Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride(Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride) - 药物靶点：PPARγ x PRKAB1 x SGLT2_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lobeglitazone/D745/D150、CKD-383

靶点

PPARγ x PRKAB1 x SGLT2

作用方式

激动剂、激活剂、抑制剂

作用机制

PPARγ激动剂(过氧化物酶体增长因子活化受体γ激动剂)、PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂)、SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症-

原研机构

Chong Kun Dang Pharmaceutical Corp.

在研机构

Chong Kun Dang Pharmaceutical Corp.

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride 相关的临床试验

NCT06695572

/ Completed临床1期

An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers

This study is a randomized, open-label, single dose, crossover study to evaluate the food effect of CKD-383 in healthy volunteers

开始日期2024-11-06

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

NCT06492655

/ Not yet recruiting临床1期

A Randomized, Open-label, Single Dose, Crossover, Phase 1 Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-383 in Healthy Volunteers

This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers

开始日期2024-07-04

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

NCT06483243

/ Completed临床1期

A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, and D150 for Healthy Subjects in Fed State

This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state

开始日期2024-04-04

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

100 项与 Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride 相关的专利（医药）

登录后查看更多信息

100 项与 Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride 相关的药物交易

登录后查看更多信息